Global Integrated Organ Support Therapies Market - 2025-2033
Description
Integrated Organ Support Therapies Market Size
Integrated Organ Support Therapies Market Size reached US$ 4.11 Billion in 2024 and is expected to reach US$ 6.69 Billion by 2033, growing at a CAGR of 5.6% during the forecast period 2025-2033.
Integrated Organ Support Therapies Market The integrated organ support therapies market is poised for continued expansion, underpinned by technological innovations (e.g., AI-enabled monitoring), growing critical care demands, and enhanced multi-organ platform adoption. Efforts to reduce device costs, streamline regulatory pathways, and develop portable solutions will further accelerate market penetration, particularly in emerging economies. Innovations in extracorporeal therapies, including ECMO (Extracorporeal Membrane Oxygenation) and CRRT (Continuous Renal Replacement Therapy), have enhanced the efficacy and safety of organ support, leading to increased adoption in intensive care units.
Integrated Organ Support Therapies Market Dynamics: Drivers & Restraints
The rising prevalence of chronic and acute organ failures is significantly driving the integrated organ support therapies market growth
Multi-organ failure is a common consequence of conditions like sepsis, trauma, and severe COVID-19. According to the article published by ScienceDirect, multiple organ failure (MOF) is the cause of 50–80% of all deaths in surgical intensive care units. This rising incidence directly boosts the demand for multi-functional organ support systems such as ADVOS, which can simultaneously support the liver, kidney, and lungs.
Additionally, nearly 750,000 patients per year in the United States and an estimated 2 million patients worldwide are affected by kidney failure. These trends have dramatically raised the need for renal support, especially CRRT in ICUs. Acute and chronic liver failure, often associated with alcoholic liver disease, hepatitis, or drug toxicity (e.g., acetaminophen overdose), necessitate extracorporeal liver support. Devices like MARS (Molecular Adsorbent Recirculating System) and ADVOS have shown improved outcomes in liver detoxification and patient stabilization.
As the global burden of organ failure, whether due to age, chronic disease, or acute illness, increases, hospitals and critical care units are compelled to adopt integrated, multi-organ support systems. This rising clinical need is directly propelling market growth, pushing innovation in combined organ support platforms, and expanding their use beyond traditional single-organ devices.
Risks and complications associated with organ support therapies are hampering the integrated organ support therapies market
One of the most serious complications associated with organ support therapies is the increased risk of infection, especially with invasive devices like extracorporeal membrane oxygenation (ECMO) and continuous renal replacement therapy (CRRT). Many organ support devices, particularly ECMO and CRRT, involve circulating blood outside the body, which further poses a significant risk of blood clot formation or bleeding. These risks may hamper the growth of the market.
Multi-organ support systems are often technologically complex, increasing the risk of device malfunction, calibration errors, and staff mismanagement. This complexity limits use to highly trained centers, restricting broader market penetration. Not all patients benefit from organ support therapies. In cases of irreversible organ damage, therapies like ECMO or CRRT may prolong suffering without improving survival, raising ethical concerns and making clinicians cautious.
Integrated Organ Support Therapies Market Segment Analysis
The global integrated organ support therapies market is segmented based on therapy type, modality, application, end-user, and region.
The multi-organ failure from the application segment is expected to hold 36.54% of the market share in 2024 in the integrated organ support therapies market
Multi-organ failure (MOF) frequently occurs in critically ill patients due to sepsis, trauma, or acute illnesses like COVID-19. It is associated with extremely high ICU mortality rates, often exceeding 50%. These patients require simultaneous support for lungs, kidneys, liver, and sometimes the heart, making them ideal candidates for integrated support platforms.
Patients with failure of two or more organs cannot be managed effectively using single-organ systems alone. Multi-organ platforms like ADVOS (which supports liver, kidney, and lung function) or Baxter’s PrisMax system (which combines CRRT with other blood purification options) are specifically designed to address such complex cases.
Using one integrated system instead of multiple standalone devices for different organs reduces treatment complexity, staffing burdens, and overall cost per patient. Hospitals prefer such platforms when managing patients with MOF to streamline care. Companies are increasingly targeting multi-organ failure as their core use case due to the high unmet need and greater willingness of hospitals to invest in advanced technologies for these critically ill patients.
Integrated Organ Support Therapies Market Geographical Analysis
North America is expected to dominate the global integrated organ support therapies market with a 42.21% share in 2024
The North America region is expected to hold the largest market share over the forecast period, owing to the rising prevalence of chronic diseases and critical illnesses, and high healthcare expenditure. Chronic diseases and critical illnesses are the leading causes of organ failure in the region, especially in the United States, directly driving the need for integrated organ support therapies. Conditions such as cardiovascular diseases, chronic kidney disease (CKD), diabetes, and respiratory diseases significantly increase the incidence of multi-organ failure, where organ support therapies become crucial for patient survival.
Leading global manufacturers such as Baxter International, Medtronic, and Fresenius Medical Care North America are headquartered or have strong operational bases in the U.S. This ensures early access to new products, rapid deployment, and robust after-sales support.
For instance, in February 2025, Vantive, formerly the Baxter Kidney Care segment, launched as a new standalone vital organ therapy company following the completion of its acquisition by funds managed by global investment firm Carlyle from Baxter International Inc. Vantive builds on a 70-year legacy as a leader in kidney care innovation to advance its mission of extending lives and expanding possibilities.
Asia-Pacific is growing at the fastest pace in the Integrated organ support therapies market, holding 21.71% of the market share
Asia-Pacific countries are experiencing a surge in chronic diseases such as diabetes, hypertension, and liver disease, which are major risk factors for organ failure. Additionally, sepsis, trauma, and acute infections continue to drive ICU admissions requiring organ support. Governments in countries like India, Japan, China, and Southeast Asia are investing heavily in upgrading hospital infrastructure, especially intensive care units. This creates a broader base for deploying advanced organ support systems like ECMO, CRRT, and multi-organ platforms.
Medical device companies are increasingly targeting Asia-Pacific for market expansion through local partnerships, manufacturing, and distribution, making technologies more accessible and affordable. For instance, Baxter, Fresenius, and Medtronic have expanded their CRRT and blood purification product lines across Asia through regional offices, training programs, and lower-cost versions adapted for local use.
Integrated Organ Support Therapies Market Top Companies
Top companies in the integrated organ support therapies market include Emulate, Inc., Baxter International, Fresenius Medical Care AG, Getinge AB, LivaNova, Inc., Asahi Kasei Corporation, ADVITOS GmbH, NIHON KOHDEN CORPORATION, Vapotherm, and Fisher & Paykel Healthcare Limited, among others.
The global integrated organ support therapies market report delivers a detailed analysis with 78 key tables, more than 77 visually impactful figures, and 167 pages of expert insights, providing a complete view of the market landscape.
Integrated Organ Support Therapies Market Size reached US$ 4.11 Billion in 2024 and is expected to reach US$ 6.69 Billion by 2033, growing at a CAGR of 5.6% during the forecast period 2025-2033.
Integrated Organ Support Therapies Market The integrated organ support therapies market is poised for continued expansion, underpinned by technological innovations (e.g., AI-enabled monitoring), growing critical care demands, and enhanced multi-organ platform adoption. Efforts to reduce device costs, streamline regulatory pathways, and develop portable solutions will further accelerate market penetration, particularly in emerging economies. Innovations in extracorporeal therapies, including ECMO (Extracorporeal Membrane Oxygenation) and CRRT (Continuous Renal Replacement Therapy), have enhanced the efficacy and safety of organ support, leading to increased adoption in intensive care units.
Integrated Organ Support Therapies Market Dynamics: Drivers & Restraints
The rising prevalence of chronic and acute organ failures is significantly driving the integrated organ support therapies market growth
Multi-organ failure is a common consequence of conditions like sepsis, trauma, and severe COVID-19. According to the article published by ScienceDirect, multiple organ failure (MOF) is the cause of 50–80% of all deaths in surgical intensive care units. This rising incidence directly boosts the demand for multi-functional organ support systems such as ADVOS, which can simultaneously support the liver, kidney, and lungs.
Additionally, nearly 750,000 patients per year in the United States and an estimated 2 million patients worldwide are affected by kidney failure. These trends have dramatically raised the need for renal support, especially CRRT in ICUs. Acute and chronic liver failure, often associated with alcoholic liver disease, hepatitis, or drug toxicity (e.g., acetaminophen overdose), necessitate extracorporeal liver support. Devices like MARS (Molecular Adsorbent Recirculating System) and ADVOS have shown improved outcomes in liver detoxification and patient stabilization.
As the global burden of organ failure, whether due to age, chronic disease, or acute illness, increases, hospitals and critical care units are compelled to adopt integrated, multi-organ support systems. This rising clinical need is directly propelling market growth, pushing innovation in combined organ support platforms, and expanding their use beyond traditional single-organ devices.
Risks and complications associated with organ support therapies are hampering the integrated organ support therapies market
One of the most serious complications associated with organ support therapies is the increased risk of infection, especially with invasive devices like extracorporeal membrane oxygenation (ECMO) and continuous renal replacement therapy (CRRT). Many organ support devices, particularly ECMO and CRRT, involve circulating blood outside the body, which further poses a significant risk of blood clot formation or bleeding. These risks may hamper the growth of the market.
Multi-organ support systems are often technologically complex, increasing the risk of device malfunction, calibration errors, and staff mismanagement. This complexity limits use to highly trained centers, restricting broader market penetration. Not all patients benefit from organ support therapies. In cases of irreversible organ damage, therapies like ECMO or CRRT may prolong suffering without improving survival, raising ethical concerns and making clinicians cautious.
Integrated Organ Support Therapies Market Segment Analysis
The global integrated organ support therapies market is segmented based on therapy type, modality, application, end-user, and region.
The multi-organ failure from the application segment is expected to hold 36.54% of the market share in 2024 in the integrated organ support therapies market
Multi-organ failure (MOF) frequently occurs in critically ill patients due to sepsis, trauma, or acute illnesses like COVID-19. It is associated with extremely high ICU mortality rates, often exceeding 50%. These patients require simultaneous support for lungs, kidneys, liver, and sometimes the heart, making them ideal candidates for integrated support platforms.
Patients with failure of two or more organs cannot be managed effectively using single-organ systems alone. Multi-organ platforms like ADVOS (which supports liver, kidney, and lung function) or Baxter’s PrisMax system (which combines CRRT with other blood purification options) are specifically designed to address such complex cases.
Using one integrated system instead of multiple standalone devices for different organs reduces treatment complexity, staffing burdens, and overall cost per patient. Hospitals prefer such platforms when managing patients with MOF to streamline care. Companies are increasingly targeting multi-organ failure as their core use case due to the high unmet need and greater willingness of hospitals to invest in advanced technologies for these critically ill patients.
Integrated Organ Support Therapies Market Geographical Analysis
North America is expected to dominate the global integrated organ support therapies market with a 42.21% share in 2024
The North America region is expected to hold the largest market share over the forecast period, owing to the rising prevalence of chronic diseases and critical illnesses, and high healthcare expenditure. Chronic diseases and critical illnesses are the leading causes of organ failure in the region, especially in the United States, directly driving the need for integrated organ support therapies. Conditions such as cardiovascular diseases, chronic kidney disease (CKD), diabetes, and respiratory diseases significantly increase the incidence of multi-organ failure, where organ support therapies become crucial for patient survival.
Leading global manufacturers such as Baxter International, Medtronic, and Fresenius Medical Care North America are headquartered or have strong operational bases in the U.S. This ensures early access to new products, rapid deployment, and robust after-sales support.
For instance, in February 2025, Vantive, formerly the Baxter Kidney Care segment, launched as a new standalone vital organ therapy company following the completion of its acquisition by funds managed by global investment firm Carlyle from Baxter International Inc. Vantive builds on a 70-year legacy as a leader in kidney care innovation to advance its mission of extending lives and expanding possibilities.
Asia-Pacific is growing at the fastest pace in the Integrated organ support therapies market, holding 21.71% of the market share
Asia-Pacific countries are experiencing a surge in chronic diseases such as diabetes, hypertension, and liver disease, which are major risk factors for organ failure. Additionally, sepsis, trauma, and acute infections continue to drive ICU admissions requiring organ support. Governments in countries like India, Japan, China, and Southeast Asia are investing heavily in upgrading hospital infrastructure, especially intensive care units. This creates a broader base for deploying advanced organ support systems like ECMO, CRRT, and multi-organ platforms.
Medical device companies are increasingly targeting Asia-Pacific for market expansion through local partnerships, manufacturing, and distribution, making technologies more accessible and affordable. For instance, Baxter, Fresenius, and Medtronic have expanded their CRRT and blood purification product lines across Asia through regional offices, training programs, and lower-cost versions adapted for local use.
Integrated Organ Support Therapies Market Top Companies
Top companies in the integrated organ support therapies market include Emulate, Inc., Baxter International, Fresenius Medical Care AG, Getinge AB, LivaNova, Inc., Asahi Kasei Corporation, ADVITOS GmbH, NIHON KOHDEN CORPORATION, Vapotherm, and Fisher & Paykel Healthcare Limited, among others.
The global integrated organ support therapies market report delivers a detailed analysis with 78 key tables, more than 77 visually impactful figures, and 167 pages of expert insights, providing a complete view of the market landscape.
Table of Contents
180 Pages
- 1. Market Introduction and Scope
- 1.1. Objectives of the Report
- 1.2. Report Coverage & Definitions
- 1.3. Report Scope
- 2. Executive Insights and Key Takeaways
- 3. Market Highlights and Strategic Takeaways
- 3.1. Key Trends and Future Projections
- 4. Snippet by Therapy Type
- 4.1. Snippet by Modality
- 4.2. Snippet by Application
- 4.3. Snippet by End-User
- 4.4. Snippet by Region
- 5. Dynamics
- 5.1. Impacting Factors
- 5.1.1. Drivers
- 5.1.1.1. Rising Prevalence of Chronic and Acute Organ Failures
- 5.1.1.2. Emergence of Multi-Organ Platforms as Bridge Therapies to Transplant
- 5.1.1.3. Shift Toward Personalized Critical Care
- 5.1.2. Restraints
- 5.1.2.1. Risks and Complications Associated with Organ Support Therapies
- 5.1.2.2. Lack of Unified Protocols for Multi-Organ Support Use
- 5.1.2.3. Ethical and End-of-Life Decision Complexity
- 5.1.3. Opportunity
- 5.1.3.1. Development of Modular, Portable Multi-Organ Support Devices
- 5.1.3.2. Integration of AI and Predictive Analytics for Dynamic Organ Support
- 5.1.4. Impact Analysis
- 6. Strategic Insights and Industry Outlook
- 6.1. Market Leaders and Pioneers
- 6.1.1. Emerging Pioneers and Prominent Players
- 6.1.2. Established Leaders with the Largest Marketing Brand
- 6.1.3. Market Leaders with Established Products
- 6.2. Latest Developments and Breakthroughs
- 6.3. Regulatory and Reimbursement Landscape
- 6.3.1. North America
- 6.3.2. Europe
- 6.3.3. Asia Pacific
- 6.3.4. South America
- 6.3.5. Middle East & Africa
- 6.4. Porter’s Five Forces Analysis
- 6.5. Supply Chain Analysis
- 6.6. Patent Analysis
- 6.7. SWOT Analysis
- 6.8. Unmet Needs and Gaps
- 6.9. Recommended Strategies for Market Entry and Expansion
- 6.10. Pricing Analysis and Price Dynamics
- 7. Integrated Organ Support Therapies Market, By Therapy Type
- 7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
- 7.1.2. Market Attractiveness Index, By Therapy Type
- 7.2. Extracorporeal Membrane Oxygenation (ECMO)*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.2.3. Veno-Venous (VV)
- 7.2.4. Veno-Arterial (VA)
- 7.2.5. Arterio-Venous (AV)
- 7.3. Continuous Renal Replacement Therapy (CRRT)
- 7.3.1. Continuous Venovenous Hemofiltration (CVVH)
- 7.3.2. Continuous Venovenous Hemodialysis (CVVHD)
- 7.3.3. Continuous Venovenous Hemodiafiltration (CVVHDF)
- 7.3.4. Slow Continuous Ultrafiltration (SCUF)
- 7.4. Extracorporeal CO₂ Removal (ECCO₂R)
- 7.5. Liver Support Systems
- 7.5.1. Molecular Adsorbent Recirculating System
- 7.5.2. Bioartificial Liver Support
- 7.6. Cardiac Assist Devices
- 7.6.1. Intra-aortic Balloon Pump
- 7.6.2. Ventricular Assist Devices
- 7.6.3. Total Artificial Organs
- 8. Integrated Organ Support Therapies Market, By Modality
- 8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
- 8.1.2. Market Attractiveness Index, By Modality
- 8.2. Portable/Transportable Devices*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Bedside Devices
- 8.4. Implantable Devices
- 9. Integrated Organ Support Therapies Market, By Application
- 9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.1.2. Market Attractiveness Index, By Application
- 9.2. Respiratory Failure*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. Cardiac Failure
- 9.4. Liver Failure
- 9.5. Kidney Failure
- 9.6. Multi-Organ Failure
- 10. Integrated Organ Support Therapies Market, By End-User
- 10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.1.2. Market Attractiveness Index, By End-User
- 10.2. Hospitals*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 10.3. Specialty Clinics
- 10.4. Ambulatory Surgical Centers
- 10.5. Intensive Care Units (ICUs)
- 11. Integrated Organ Support Therapies Market, By Regional Market Analysis and Growth Opportunities
- 11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 11.1.1.1. Market Attractiveness Index, By Region
- 11.1.2. North America
- 11.1.2.1. Introduction
- 11.1.2.2. Key Region-Specific Dynamics
- 11.1.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
- 11.1.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
- 11.1.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.1.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.1.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.1.2.7.1. U.S.
- 11.1.2.7.2. Canada
- 11.1.2.7.3. Mexico
- 11.1.3. Europe
- 11.1.3.1. Introduction
- 11.1.3.2. Key Region-Specific Dynamics
- 11.1.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
- 11.1.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
- 11.1.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.1.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.1.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.1.3.7.1. Germany
- 11.1.3.7.2. UK
- 11.1.3.7.3. France
- 11.1.3.7.4. Spain
- 11.1.3.7.5. Italy
- 11.1.3.7.6. Rest of Europe
- 11.1.4. Asia-Pacific
- 11.1.4.1. Introduction
- 11.1.4.2. Key Region-Specific Dynamics
- 11.1.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
- 11.1.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
- 11.1.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.1.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.1.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.1.4.7.1. China
- 11.1.4.7.2. India
- 11.1.4.7.3. Japan
- 11.1.4.7.4. South Korea
- 11.1.4.7.5. Rest of Asia-Pacific
- 11.1.5. South America
- 11.1.5.1. Introduction
- 11.1.5.2. Key Region-Specific Dynamics
- 11.1.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
- 11.1.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
- 11.1.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.1.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.1.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.1.5.7.1. Brazil
- 11.1.5.7.2. Argentina
- 11.1.5.7.3. Rest of South America
- 11.1.6. Middle East and Africa
- 11.1.6.1. Introduction
- 11.1.6.2. Key Region-Specific Dynamics
- 11.1.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
- 11.1.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
- 11.1.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.1.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 12. Competitive Landscape and Market Positioning
- 13. Competitive Overview and Key Market Players
- 13.1. Market Share Analysis and Positioning Matrix
- 13.2. Strategic Partnerships, Mergers & Acquisitions
- 13.3. Key Developments in Product Portfolios and Innovations
- 13.4. Company Benchmarking
- 14. Company Profiles
- 14.1. Emulate, Inc.*
- 14.1.1. Company Overview
- 14.1.2. Product Portfolio
- 14.1.2.1. Product Description
- 14.1.2.2. Product Key Performance Indicators (KPIs)
- 15. Financial Overview
- 15.1. Company Revenue
- 15.1.1. Geographical Revenue Shares
- 15.1.1.1. Revenue Forecasts
- 15.1.2. Key Developments
- 15.1.2.1. Mergers & Acquisitions
- 15.1.2.2. Key Product Development Activities
- 15.1.2.3. Regulatory Approvals, etc.
- 15.1.3. SWOT Analysis
- 15.2. Baxter International Inc.
- 15.3. Fresenius Medical Care AG
- 15.4. Getinge AB
- 15.5. LivaNova, Inc.
- 15.6. Asahi Kasei Corporation
- 15.7. ADVITOS GmbH
- 15.8. NIHON KOHDEN CORPORATION
- 15.9. Vapotherm
- 15.10. Fisher & Paykel Healthcare Limited (*LIST NOT EXHAUSTIVE)
- 16. Assumptions and Research Methodology
- 16.1. Data Collection Methods
- 16.2. Data Triangulation
- 16.3. Forecasting Techniques
- 16.4. Data Verification and Validation
- 17. Appendix
- 17.1. About Us and Services
- 17.2. Contact Us
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
